News

April 12, 2019

Age, Obesity, Comorbidities Linked with Severe Fatigue Among Non-Hodgkin’s Lymphoma Survivors

News

While a significant proportion of non-Hodgkin’s lymphoma survivors suffer from severe fatigue, the type of initial treatment and Rituxan (rituxumab) use did not influence this outcome, a new study shows. Instead, ... Read more

April 11, 2019

Phase 1 Trial of CA-4948 Recruiting Non-Hodgkin’s Lymphoma Patients

News

A Phase 1 clinical trial is recruiting relapsed or refractory non-Hodgkin’s lymphoma patients to determine the safest and most effective dose of the oral therapy CA-4948. The trial is now treating patients ... Read more

April 9, 2019

First CTCL Patients Enrolled in Phase 2 Trial of Topical Treatment WP1220

News

The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the first two participants. The trial, to assess WP1220‘s safety and ... Read more

April 5, 2019

Three-tiered Combination Stimulates Immune System to Attack Lymphoma Cells, Phase 1/2 Trial Shows

News

A combination of oral Imbruvica (ibrutinib), intratumoral CpG, and local low-dose radiation stimulates the immune system to safely and effectively attack lymphoma cells, according to a new study. The study, ... Read more

April 4, 2019

TG Therapeutics’ Umbralisib Proves Safe, Effective for Previously Treated Marginal Zone Lymphoma

News

TG Therapeutics‘ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising efficacy and safety in patients with relapsed or refractory marginal zone lymphoma, reducing cancer volume in more than half of ... Read more

April 2, 2019

Leukemia & Lymphoma Society’s Silicon Valley Chapter Raises $297K in ‘Student of the Year’ Contest

News

The Leukemia & Lymphoma Society’s (LLS) Silicon Valley Student of the Year drive netted more than $297,000 to support the organization’s research and patient support efforts. Funds were raised through the ... Read more

March 29, 2019

UK’s NICE Recommends Adcetris as Second-line Treatment for Certain CTCL Patients

News

After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous T-cell ... Read more

March 28, 2019

Revlimid/Rituxan Combo Shows Promise in Follicular, Marginal Zone Lymphomas

News

Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination ... Read more

March 26, 2019

Trials to Test Abexinostat in Heavily Treated DLBCL, Follicular Lymphoma

News

Xynomic Pharma is preparing two new Phase 2 trials in China to explore the activity of its investigational HDAC inhibitor, abexinostat, as third-line therapy for diffuse large B-cell lymphoma (DLBCL) ... Read more

March 22, 2019March 22, 2019

Scotland Rejects NHS Access to Kymriah for Aggressive Diffuse Large B-cell Lymphoma

News

Scotland’s healthcare system has rejected the use of Novartis‘ immunotherapy Kymriah (tisagenlecleucel) for adults with aggressive diffuse large B-cell lymphoma (DLBCL) who failed at least two prior lines of therapy. The Scottish Medicines Consortium (SMC) ... Read more